• Explore /
  • Poster
  • / Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.

Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.

Abstract Poster

Authors

null

Ovidio Fernandez Calvo

Complejo Hospitalario de Ourense, Ourense, Spain

Ovidio Fernandez Calvo , Eva Fernandez Parra , Begoña Perez-Valderrama , Begoña Mellado , Maria Ochoa de Olza , Daniel E. Castellano , Montserrat Domenech , Susana Hernando Polo , Urbano Anido , Jose Angel Arranz Arija , Cristina Caballero , M Jose Juan , Ignacio Duran , Marc Campayo , Monica Serrano , Miguel Angel Climent

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01518283

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 167)

DOI

10.1200/jco.2015.33.7_suppl.167

Abstract #

167

Poster Bd #

H3

Abstract Disclosures

Similar Posters

First Author: Miguel Angel Climent Duran

First Author: Padmanee Sharma

First Author: Joaquin Mateo

Poster

2015 Genitourinary Cancers Symposium

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Alice Clement-Zhao